Gh Release Research Peptides
Overview
13 research peptides demonstrate gh release properties. This collection covers their mechanisms, evidence base, and research applications.
Ipamorelin
Preclinical | Growth Hormone Secretagogue
Ipamorelin is the most selective growth hormone secretagogue (GHS) available, a synthetic pentapeptide (MW ~711.86 g/mol, formula C38H49N9O5) that stimulates pulsatile GH release from the pituitary gland without significantly affecting cortisol,...
Mechanism: Ipamorelin (sequence: Aib-His-D-2Nal-D-Phe-Lys-NH2) selectively binds to the Growth Hormone Secretagogue Receptor (GHS-R1a) on anterior pituitary somatotroph cells, increasing cAMP and activating...
CJC-1295
Preclinical | Growth Hormone Secretagogue
CJC-1295 is a synthetic analogue of growth hormone-releasing hormone (GHRH) originally developed by ConjuChem Technologies for HIV-associated lipodystrophy. It exists in two forms: with DAC (Drug Affinity Complex) for extended half-life of 5.8-8.
Mechanism: CJC-1295 binds to GHRH receptors (GHRHR) on pituitary somatotroph cells, activating intracellular cAMP signaling to stimulate both the transcription of the GH gene and pulsatile release of endogenous...
Sermorelin
Phase I–II Clinical Trials | Growth Hormone Secretagogue
Sermorelin is a synthetic 29-amino-acid peptide (MW ~3357.9 g/mol) corresponding to the first 29 amino acids of naturally occurring growth hormone-releasing hormone (GHRH).
Mechanism: Sermorelin binds to GHRH receptors (GHRHR) on somatotroph cells in the anterior pituitary gland, stimulating both transcription of the HGH gene and pulsatile release of endogenous growth hormone.
Tesamorelin
FDA Approved | Growth Hormone Secretagogue
Tesamorelin (tesamorelin acetate) is a synthetic 44-amino-acid analog of human growth hormone-releasing hormone (GHRH) and the only FDA-approved medication for reducing excess abdominal fat in HIV-infected adults with lipodystrophy, marketed as...
Mechanism: Tesamorelin binds to and stimulates human GRF (growth hormone-releasing factor) receptors on the anterior pituitary with similar potency as endogenous GRF, stimulating synthesis and release of...
GHRP-6
Preclinical | Growth Hormone Secretagogue
GHRP-6 (Growth Hormone-Releasing Peptide 6) is a synthetic hexapeptide that functions as a potent growth hormone secretagogue by binding to the ghrelin receptor (GHS-R1a).
Mechanism: GHRP-6 functions as a synthetic ghrelin mimetic by binding to GHS-R1a in the pituitary and hypothalamus, triggering pulsatile GH release and raising IGF-1 levels.
GHRP-2
Phase I–II Clinical Trials | Growth Hormone Secretagogue
GHRP-2 (pralmorelin) is a synthetic hexapeptide growth hormone secretagogue (D-Ala-D-2-Nal-Ala-Trp-D-Phe-Lys-NH2, MW ~817.97 g/mol) that stimulates potent, dose-dependent GH release via the ghrelin receptor (GHS-R).
Mechanism: GHRP-2 (C45H55N9O6) binds to and activates ghrelin (GH secretagogue) receptors on pituitary somatotrophs, triggering robust pulsatile GH release.
MK-677
Phase I–II Clinical Trials | Growth Hormone Secretagogue
MK-677 (Ibutamoren) is a potent, long-acting, orally-active, non-peptide ghrelin receptor (GHS-R1a) agonist that stimulates growth hormone release without injections.
Mechanism: MK-677 binds to the ghrelin receptor (GHS-R1a) in the pituitary gland and hypothalamus, mimicking the hunger hormone ghrelin.
Hexarelin
Phase I–II Clinical Trials | Growth Hormone Secretagogue
Hexarelin is a synthetic hexapeptide growth hormone secretagogue that binds to the ghrelin receptor (GHS-R1a). It is considered one of the most potent GHRPs available, stimulating greater GH release than GHRH alone.
Mechanism: Hexarelin binds to and activates the ghrelin/growth hormone secretagogue receptor (GHS-R1a) in the pituitary and hypothalamus through a triple mechanism: direct stimulation of pituitary somatotroph...
Alexamorelin
Preclinical | Growth Hormone Secretagogue
Alexamorelin is a synthetic growth hormone-releasing peptide (GHRP) structurally related to GHRP-6. It was investigated as a GH secretagogue in limited preclinical studies but never advanced to meaningful clinical development.
Mechanism: Alexamorelin is believed to act as a ghrelin receptor (GHS-R1a) agonist, stimulating growth hormone release from the anterior pituitary.
Tabimorelin
Phase I–II Clinical Trials | Growth Hormone Secretagogue
Tabimorelin (NN703) is a synthetic, orally active growth hormone secretagogue developed by Novo Nordisk. It completed Phase II clinical trials demonstrating significant GH release in both healthy subjects and GH-deficient adults.
Mechanism: Tabimorelin acts as a ghrelin receptor (GHS-R1a) agonist, stimulating growth hormone release from the anterior pituitary gland. It has oral bioavailability, distinguishing it from injectable GHRPs.
Macimorelin
FDA Approved | Growth Hormone Secretagogue
Macimorelin (Macrilen) is an orally active growth hormone secretagogue that received FDA approval in December 2017 as a diagnostic test for adult growth hormone deficiency (AGHD). It is the only FDA-approved oral GH secretagogue in the United States.
Mechanism: Macimorelin is a ghrelin receptor (GHS-R1a) agonist. After oral administration, it stimulates growth hormone release from the anterior pituitary in a dose-dependent manner.
HGH Fragment 176-191
Preclinical | Growth Hormone Fragment
HGH Fragment 176-191 is a synthetic peptide corresponding to the C-terminal portion (amino acids 176-191) of human growth hormone. This 16-amino acid fragment was identified as the region of GH responsible for its lipolytic (fat-burning) activity.
Mechanism: HGH Fragment 176-191 mimics the lipolytic action of the C-terminal loop of growth hormone. It stimulates lipolysis (fat breakdown) and inhibits lipogenesis (fat formation) in adipose tissue,...
Anamorelin
Phase III / Regulatory Approval (Japan) | Growth Hormone Secretagogue
Anamorelin is a synthetic, orally active ghrelin receptor (GHS-R1a) agonist developed for the treatment of cancer-related cachexia.
Mechanism: Anamorelin acts as a selective agonist at GHS-R1a, the same G protein-coupled receptor targeted by endogenous ghrelin.
Related Products
Related Research News
CJC-1295 with DAC and Ipamorelin: Growth Hormone Research Guide
CJC-1295 with DAC and Ipamorelin represent key compounds in growth hormone research, targeting distinct pathways for GH and IGF-1 signaling. CJC-1295 with DAC acts as a long-acting GHRH analogue with a half-life of 5.8 to 8.1 days, while Ipamorelin functions as a selective growth hormone secretagogue via the ghrelin receptor. Together, they support studies on metabolism, recovery, and body composition.
CJC-1295 + Ipamorelin: Growth Hormone Stack Mechanics
CJC-1295 and Ipamorelin form the most studied growth hormone peptide combination in research. They target separate receptor pathways to boost GH secretion through the somatotropic axis. This stack produces amplified GH pulses, with preclinical data showing 3 to 5 times baseline levels versus 1.5 to 2 times alone.
Synergistic Growth Hormone Effects of Sermorelin and Ipamorelin Blend
Research peptides Sermorelin and Ipamorelin may work together to boost growth hormone release from pituitary cells through distinct pathways. Sermorelin mimics the active part of natural GHRH, while Ipamorelin targets GHS-R1a receptors selectively. Laboratory studies indicate this combination could produce higher hGH peaks than either alone, with potential anabolic benefits via IGF-1.